Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2012
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms SOCS-B
- 19 May 2012 Company added as trial sponsor as reported by EudraCT.
- 19 May 2012 Actual end date 30 Jul 2011 added as reported by EudraCT.
- 19 May 2012 Status changed from recruiting to discontinued as reported by EudraCT.